Annals of Surgical Oncology

, Volume 19, Issue 2, pp 519–526 | Cite as

Neoadjuvant Chemotherapy Increases the Rate of Breast Conservation in Lobular-Type Breast Cancer Patients

  • Florian FitzalEmail author
  • Martina Mittlboeck
  • Guenther Steger
  • Rupert Bartsch
  • Margaretha Rudas
  • Peter Dubsky
  • Otto Riedl
  • Raimund Jakesz
  • Michael Gnant
Breast Oncology



Our study aims to determine whether patients with lobular-type breast cancer have significantly improved rates of breast conservation (BCT) after neoadjuvant chemotherapy (nCT).


Patients who received nCT and surgery within three prospective trials between 1995 and 2007 at the Medical University of Vienna were retrospectively analyzed.


325 patients had median follow-up of 53 months; 21% had lobular cancer, and 70% of these women were initially scheduled for mastectomy (MX). Twenty-one finally received BCT, yielding a MX–BCT turnover rate of 45%. Of patients primarily scheduled for BCT, 20% had to finally undergo MX in lobular cancer. The 256 patients with ductal-type breast cancer finally had a MX–BCT turnover rate of 52% (p = 0.561 versus lobular) and a BCT–MX turnover rate of 15% (p = 0.933 versus lobular). Secondary MX after initial BCT was necessary in 2% (ductal) and 10% (lobular, p = 0.110). There was no difference in local recurrence in lobular- as compared with ductal-type breast cancer patients after BCT (2.7% versus 10%, p = 0.135), nor was a difference seen in lobular breast cancer patients when comparing BCT with MX (2.7% versus 3.4%, p = 0.795). Tumor type was not an independent predictor for either BCT or local recurrence.


We do not suggest excluding patients with lobular-type breast cancer who are primarily scheduled for MX from nCT, since BCT rates may still increase by 45% without influencing the oncologic outcome.


Breast Cancer Breast Cancer Patient Sentinel Node Biopsy Inflammatory Breast Cancer Pegfilgrastim 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors are grateful to Natalija Frank for her dedicated work on patients and building up the database, and to Karl Thomanek for language improvement.


  1. 1.
    Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003;21:2600–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Charfare H, Limongelli S, Purushotham AD. Neoadjuvant chemotherapy in breast cancer. Br J Surg. 2005;92:14–23.PubMedCrossRefGoogle Scholar
  3. 3.
    Jones RL, Smith IE. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol. 2006;7:869–74.PubMedCrossRefGoogle Scholar
  4. 4.
    Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94:1189–200.PubMedCrossRefGoogle Scholar
  5. 5.
    Kiebert GM, de Haes JC, van de Velde CJ. The impact of breast-conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients: a review. J Clin Oncol. 1991;9:1059–70.PubMedGoogle Scholar
  6. 6.
    Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188–94.PubMedCrossRefGoogle Scholar
  7. 7.
    Steger GG, Greil R, Jakesz R, et al. A randomized phase III study comparing epirubicin, doxetacel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer—first results of the ABCSG Trial 24. Annual Meeting of the European Society of Medical Oncology. 2009.Google Scholar
  8. 8.
    Purushotham A, Pinder S, Cariati M, Harries M, Goldhirsch A. Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast? J Clin Oncol. 2010;28:3552–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Katz A, Saad ED, Porter P, Pusztai L. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol. 2007;8:55–62.PubMedCrossRefGoogle Scholar
  10. 10.
    Soucy G, Belanger J, Leblanc G, et al. Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact? J Am Coll Surg. 2008;206:1116–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Boughey JC, Wagner J, Garrett BJ, et al. Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol. 2009;16:1606–11.PubMedCrossRefGoogle Scholar
  12. 12.
    Steger G, Kubista E, Hausmaninger H, et al. 6 vs. 3 Cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14. J Clin Oncol. 2004;22:553.Google Scholar
  13. 13.
    Taucher S, Steger GG, Jakesz R, et al. The potential risk of neoadjuvant chemotherapy in breast cancer patients—results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07). Breast Cancer Res Treat. 2008;112:309–16.PubMedCrossRefGoogle Scholar
  14. 14.
    Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;96–102.Google Scholar
  15. 15.
    Riedl O, Fitzal F, Mader N, et al. Intraoperative frozen section analysis for breast-conserving therapy in 1016 patients with breast cancer. Eur J Surg Oncol. 2009;35:264–70.PubMedCrossRefGoogle Scholar
  16. 16.
    Loibl S, von Minckwitz G, Raab G, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006;13:1434–42.PubMedCrossRefGoogle Scholar
  17. 17.
    Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res. 1990;50:7057–61.PubMedGoogle Scholar
  18. 18.
    Fitzal F, Riedl O, Wutzl L, et al. Breast-conserving surgery for T3/T4 breast cancer: an analysis of 196 patients. Breast Cancer Res Treat. 2007;103:45–52.PubMedCrossRefGoogle Scholar
  19. 19.
    Straver ME, Rutgers EJ, Rodenhuis S, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010;17:2411–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Mathieu MC, Rouzier R, Llombart-Cussac A, et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer. 2004;40:342–51.PubMedCrossRefGoogle Scholar
  21. 21.
    Newman LA, Buzdar AU, Singletary SE, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol. 2002;9:228–34.PubMedCrossRefGoogle Scholar
  22. 22.
    Cocquyt VF, Blondeel PN, Depypere HT, et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol. 2003;29:361–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Wagner J, Boughey JC, Garrett B, et al. Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. Am J Surg. 2009;198:387–91.PubMedCrossRefGoogle Scholar
  24. 24.
    Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23:41–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85.PubMedGoogle Scholar
  26. 26.
    Tubiana-Hulin M, Stevens D, Lasry S, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol. 2006;17:1228–33.PubMedCrossRefGoogle Scholar
  27. 27.
    Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110:244–54.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Florian Fitzal
    • 1
    Email author
  • Martina Mittlboeck
    • 2
  • Guenther Steger
    • 3
  • Rupert Bartsch
    • 3
  • Margaretha Rudas
    • 4
  • Peter Dubsky
    • 1
  • Otto Riedl
    • 1
  • Raimund Jakesz
    • 1
  • Michael Gnant
    • 1
  1. 1.Department of Surgery, Breast Health Care CenterMedical University of ViennaViennaAustria
  2. 2.Department of Clinical Biometrics, Breast Health Care CenterMedical University of ViennaViennaAustria
  3. 3.Department of Oncology, Breast Health Care CenterMedical University of ViennaViennaAustria
  4. 4.Department of Pathology, Breast Health Care CenterMedical University of ViennaViennaAustria

Personalised recommendations